Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Coronavirus Vaccines, Psoriasis, China Oncology And More

Executive Summary

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

Take a brief audio tour around Scrip’s Five Must-Know Things, in this episode covering major biopharmaceutical developments in the business week ended 24 July 2020.

Progress with coronavirus vaccines, a new contender in psoriasis, oncology strategy in China and a new trial in spinal muscular atrophy are on the table this week. 

Stories mentioned in this episode:

(Also see "New Pfizer/BioNTech COVID-19 Vaccine Data Confirm Prior Results, Show T-Cell Boost" - Scrip, 20 Jul, 2020.)

(Also see "Solid Phase I Results For AstraZeneca COVID-19 Vaccine, But Two Doses Needed To Hit Efficacy Goal" - Scrip, 20 Jul, 2020.)

(Also see "Lilly’s Mirikizumab Shows Superiority Vs. Cosentyx In Psoriasis" - Scrip, 17 Jul, 2020.)

(Also see "Roche Rides Partnership, Digital Wave To Widen China Oncology Drug Access" - Scrip, 20 Jul, 2020.)

(Also see "One Way To Get Ahead: Biogen To Test Spinraza Given After Novartis’s Zolgensma" - Scrip, 21 Jul, 2020.)

 

Related Content

Topics

UsernamePublicRestriction

Register

ID1131690

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel